Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2017

Filed with the SEC on Dec 14, 2017 and accepted by EDGAR at Dec 14, 2017, 16:48 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-08-01 to 2017-10-31$0us-gaap:Revenues
Revenue6 months2017-05-01 to 2017-10-31$0us-gaap:Revenues
Research and development3 months2017-08-01 to 2017-10-31$515.5kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-05-01 to 2017-10-31$943.1kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-08-01 to 2017-10-31−$1.8mus-gaap:OperatingIncomeLoss
Operating income6 months2017-05-01 to 2017-10-31−$3.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-08-01 to 2017-10-31$0us-gaap:InterestExpense
Interest expense6 months2017-05-01 to 2017-10-31$0us-gaap:InterestExpense
Net income3 months2017-08-01 to 2017-10-31−$1.8mus-gaap:NetIncomeLoss
Net income6 months2017-05-01 to 2017-10-31−$3.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-08-01 to 2017-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2017-05-01 to 2017-10-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2017-08-01 to 2017-10-31973,167,811 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2017-05-01 to 2017-10-31949,373,602 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2017-05-01 to 2017-10-31−$2.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2017-10-31$2.7mus-gaap:Cash
Current assetsAt period end2017-10-31$2.8mus-gaap:AssetsCurrent
Total assetsAt period end2017-10-31$7.9mus-gaap:Assets
Current liabilitiesAt period end2017-10-31$567.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-10-31$567.0kus-gaap:Liabilities
Shareholders' equityAt period end2017-10-31$7.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-17-003310. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.